A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- Multiple Myeloma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 400
- Started
- 4 February 2026
- Main results due
- 12 December 2028
- Study sites
- 150
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion: * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: 1. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria 2. Measurable disease at screening as assessed by central laboratory * Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody * Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria * Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration Exclusion: * Active hepatitis of infectious origin * Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM * Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab * Major surgery, (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study * Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment, or during study treatment
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Study sites(150)
Mayo Clinic Phoenix
Phoenix, Arizona, United States
Recruiting
UAMS
Little Rock, Arkansas, United States
Recruiting
City of Hope Duarte
Duarte, California, United States
Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Recruiting
University of California San Francisco
San Francisco, California, United States
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, United States
Recruiting
University of Connecticut Health Center
Farmington, Connecticut, United States
Recruiting
Yale Cancer Center
New Haven, Connecticut, United States
Recruiting
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, United States
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Recruiting
Moffit Cancer center
Tampa, Florida, United States
Recruiting
Emory University
Atlanta, Georgia, United States
Recruiting
City of Hope Chicago
Zion, Illinois, United States
Recruiting
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
Recruiting
Mission Cancer Blood
Waukee, Iowa, United States
Recruiting
University of Kansas Cancer Center
Kansas City, Kansas, United States
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Recruiting
University of Maryland School of Medicine
Baltimore, Maryland, United States
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
Boston University Medical Center
Boston, Massachusetts, United States
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Recruiting
Mount Sinai Brooklyn
Brooklyn, New York, United States
Recruiting
NYU Winthrop
Mineola, New York, United States
Recruiting
Mount Sinai Chelsea
New York, New York, United States
Recruiting
Laura and Isaac Perlmutter Cancer Center NYU ACC
New York, New York, United States
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
University of North Carolina
Chapel Hill, North Carolina, United States
Recruiting
Durham VAMC
Durham, North Carolina, United States
Recruiting
Oregon Health And Science University
Portland, Oregon, United States
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Recruiting
SCRI Oncology Partners
Nashville, Tennessee, United States
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Recruiting
St. David's South Austin Medical Center
Austin, Texas, United States
Recruiting
Baylor University Medical Center
Dallas, Texas, United States
Recruiting
UT Southwestern Medical Center
Dallas, Texas, United States
Recruiting
MD Anderson Cancer Center
Houston, Texas, United States
Recruiting
Texas Transplant Institute
San Antonio, Texas, United States
Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Recruiting
Medical College Of Wisconsin
Milwaukee, Wisconsin, United States
Recruiting
Box Hill Hospital
Box Hill, Australia
Recruiting
Mater Misericordiae Ltd
Brisbane, Australia
Recruiting
Monash Medical Centre
Clayton, Australia
Recruiting
St Vincents Hospital Melbourne
Fitzroy, Australia
Recruiting
The Alfred Hospital
Melbourne, Australia
Recruiting
Fiona Stanley Hospital
Murdoch, Australia
Recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia
Recruiting
Gold Coast University Hospital
Southport, Australia
Recruiting
Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
Campinas, Brazil
Recruiting
Fundacao Universidade de Caxias do Sul
Caxias do Sul, Brazil
Recruiting
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Recruiting
Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
Florianópolis, Brazil
Recruiting
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
Recruiting
IDOR - Regional Bahia
Salvador, Brazil
Recruiting
Funfarme Sjrp
São José do Rio Preto, Brazil
Recruiting
IDOR - Regional Sao Paulo
São Paulo, Brazil
Recruiting
Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, Brazil
Recruiting
Clinica Medica Sao Germano LTDA
São Paulo, Brazil
Recruiting
Showing 60 of 150 sites — filter to narrow it down. 150 of the 150 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07258511. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me